



**PRESS RELEASE**

**FOR IMMEDIATE DISCLOSURE**

## **ORTHO REGENERATIVE TECHNOLOGIES LAUNCHES AGORACOM PLATFORM FOR ONLINE INVESTORS OUTREACH**

Montreal, QC, February 10, 2021 – [Ortho Regenerative Technologies Inc.](#) (CSE: **ORTH**; OTCQB: **ORTIF**) (“Ortho RTI” or the “Company”), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today the launch of a 12-month online investors outreach campaign through AGORACOM for the purposes of broadening its shareholder base and targeting new investors that would be specifically interested in the Company’s business model, as well as engaging current shareholders. The Company is paying \$0 in cash for the program due to AGORACOM’s cashless and fully compliant shares for services program.

### **SIGNIFICANT EXPOSURE THROUGH AGORACOM DIGITAL NETWORK**

In 2019, AGORACOM surpassed 600 million page views, exceeded industry engagement metrics by over 400% and has served over 350 public companies.

The Ortho RTI HUB containing multiple landing pages, videos, photos and other helpful information to be updated in real-time over the next 12 months will be live on February 17 and can be found at:

<https://agoracom.com/ir/OrthoRegenerativeTechnologies>

The Ortho RTI HUB will receive significant exposure through continuous brand impression, content marketing, search engine marketing and social media engagement throughout the entire AGORACOM network. AGORACOM is the only small cap marketing firm to hold a Twitter Verified badge, averaging 4.2 million Twitter impressions per month in 2019.

### **MODERATED DISCUSSION FOR MANAGEMENT AND SHAREHOLDERS**

The Company has also launched a “CEO Verified” Discussion Forum on AGORACOM to serve as the Company’s primary social media platform to interact with both current and prospective shareholders in a fully moderated environment.

The Ortho RTI discussion forum can be found at:

<https://agoracom.com/ir/OrthoRegenerativeTechnologies/forums/discussion>

“We’re looking forward to collaborate closely with Agoracom to increase our online presence and visibility as we anticipate reaching several corporate and clinical milestones over the coming year. Their unique platform fits well with our objective of broadening our investor base while maintaining close contacts with our existing shareholders”, said Claude LeDuc, President and Chief Executive Officer of Ortho RTI.

## **SHARES FOR SERVICE**

The Company has agreed to remunerate Agoracom \$80,000 for the above-mentioned services. A first service payment of \$20,000 was made on February 1, 2021 with the remaining \$60,000 balance split equally and due on each of May 1, 2021, August 1, 2021, November 1, 2021, and February 1, 2022.

The deemed price of the securities is to be calculated using the closing price on the Canadian Securities Exchange on each of the dates as stated above.

## **About AGORACOM**

[AGORACOM](#) is the pioneer of online marketing, broadcasting, conferences and investor relations services to North American small and mid-cap public companies, with more than 300 companies served. AGORACOM is the home of more than 7.7 million investors that visited 55.2 million times and read over 600 million pages of information over the last 10 years. The average visit of 8min 43sec is more than double that of global financial sites, which can be attributed to the implementation and enforcement of the strongest moderation rules in the industry.

## **About Ortho Regenerative Technologies Inc.**

Ortho RTI is a clinical stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries. Our proprietary RESTORE technology platform is a proprietary muco-adhesive Chitosan-based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions. Ortho-R, our lead Chitosan-PRP hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment. The proprietary Chitosan-PRP combination ORTHO-R implant can be directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. A multi-site US Ortho-R Rotator Cuff Tear Repair Pilot Phase I/II clinical trial is being planned and organized. In parallel, an FDA IND submission is planned for Q1-2021. Considering the significant potential of our technology platform, Ortho RTI continues to assess new therapeutic target uses outside of the soft tissue repair field. Further information about

Ortho RTI is available on the Company's website at [www.orthorti.com](http://www.orthorti.com) and on SEDAR at [www.sedar.com](http://www.sedar.com). Also follow us on LinkedIn and Twitter.

### **Forward-Looking Statements**

This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

### **For further information, please contact:**

Claude LeDuc,

President and Chief Executive Officer

(514) 651-1282

[leduc@orthorti.com](mailto:leduc@orthorti.com)

or

Frederic Dumais,

Director Communications and Investor Relations

(514) 782-8803

[dumais@orthorti.com](mailto:dumais@orthorti.com)